AstraZeneca: FDA Approves Lumoxiti for Hairy Cell Leukemia

Date : 09/14/2018 @ 6:42AM
Source : Dow Jones News
Stock : Astrazeneca (AZN)
Quote : 36.55  0.26 (0.72%) @ 9:00PM

AstraZeneca: FDA Approves Lumoxiti for Hairy Cell Leukemia

AstraZeneca (LSE:AZN)
Historical Stock Chart

6 Months : From Jul 2018 to Jan 2019

Click Here for more AstraZeneca Charts.
   By Carlo Martuscelli 

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration approved its drug Lumoxiti for patients with hairy cell leukemia who had received other treatment previously.

The U.K. drugmaker said that this represents the first new FDA-approved medicine for the condition in more than 20 years. The approval is based on a phase 3 study of the drug that showed 75% of patients administered the drug responded to treatment.

Hairy cell leukemia is a rare kind of slow-growing leukemia in which the body produces an excess amount of lymphocytes.

Around 30% to 40% of patients with the disease who are treated will relapse between five to 10 years, AstraZeneca said. The new treatment was developed to meet this medical need.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

September 14, 2018 02:27 ET (06:27 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.